Alumis Inc. Files S-1/A for IPO

Ticker: ALMS · Form: S-1/A · Filed: Jun 24, 2024 · CIK: 1847367

Alumis Inc. S-1/A Filing Summary
FieldDetail
CompanyAlumis Inc. (ALMS)
Form TypeS-1/A
Filed DateJun 24, 2024
Risk Levelmedium
Pages15
Reading Time18 min
Key Dollar Amounts$16.00, $18.00, $600 million
Sentimentneutral

Sentiment: neutral

Topics: ipo, pharmaceutical, sec-filing

TL;DR

Alumis Inc. (formerly Esker Therapeutics) is filing an S-1/A for its IPO. Get ready for some pharma action.

AI Summary

Alumis Inc. filed an S-1/A amendment on June 24, 2024, for its initial public offering. The company, formerly Esker Therapeutics, Inc., is incorporated in Delaware and operates in the pharmaceutical preparations sector. Its principal executive offices are located at 280 East Grand Avenue, South San Francisco, California.

Why It Matters

This filing indicates Alumis Inc. is moving forward with its plan to become a publicly traded company, which could provide it with capital for further research and development in the pharmaceutical sector.

Risk Assessment

Risk Level: medium — As a pharmaceutical company pursuing an IPO, Alumis Inc. faces inherent risks related to drug development, regulatory approval, and market competition.

Key Numbers

  • 333-280068 — SEC File Number (Identifies the specific registration statement)
  • 0001847367 — Central Index Key (Unique identifier for the company in SEC filings)

Key Players & Entities

  • ALUMIS INC. (company) — Registrant
  • Esker Therapeutics, Inc. (company) — Former company name
  • 280 EAST GRAND AVENUE SOUTH SAN FRANCISCO, CALIFORNIA 94080 (company) — Principal executive offices address
  • Martin Babler (person) — President and Chief
  • June 24, 2024 (date) — Filing date

FAQ

What is the primary business of Alumis Inc.?

Alumis Inc. is classified under Standard Industrial Classification code 2834, which pertains to Pharmaceutical Preparations.

When was Alumis Inc. previously known by another name?

Alumis Inc. was formerly known as Esker Therapeutics, Inc., with a name change effective April 27, 2023.

Where are Alumis Inc.'s principal executive offices located?

The principal executive offices of Alumis Inc. are located at 280 East Grand Avenue, South San Francisco, California, 94080.

What is the SEC file number for this registration statement?

The SEC file number for this registration statement is 333-280068.

Who is listed as the President and Chief of Alumis Inc.?

Martin Babler is listed as the President and Chief of Alumis Inc.

Filing Stats: 4,447 words · 18 min read · ~15 pages · Grade level 16.2 · Accepted 2024-06-24 06:39:33

Key Financial Figures

  • $16.00 — ffering price per share will be between $16.00 and $18.00. We have applied to list our
  • $18.00 — ce per share will be between $16.00 and $18.00. We have applied to list our common sto
  • $600 million — lair. To date, we have raised more than $600 million and are backed by established blue-chip

Filing Documents

RISK FACTORS

RISK FACTORS 13 SPECIAL NOTE REGARDING FORWARD-LOOKING 73 MARKET, INDUSTRY AND OTHER DATA 75

USE OF PROCEEDS

USE OF PROCEEDS 76 DIVIDEND POLICY 78 CAPITALIZATION 79

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 84

BUSINESS

BUSINESS 103 MANAGEMENT 149

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 157 Page CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS 175 PRINCIPAL STOCKHOLDERS 181

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 184 SHARES ELIGIBLE FOR FUTURE SALE 189 CERTAIN MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS 191

UNDERWRITING

UNDERWRITING 195 LEGAL MATTERS 204 EXPERTS 204 WHERE YOU CAN FIND ADDITIONAL INFORMATION 204 INDEX TO CONSOLIDATED FINANCIAL STATEMENTS F-1 Neither we nor the underwriters have authorized anyone to provide you any information or make any representations other than those contained in this prospectus or in any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. We and the underwriters are not making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus or in any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of shares of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date. For investors outside of the United States: we have not, and the underwriters have not, done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than the United States. Persons outside of the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of common stock and the distribution of this prospectus outside of the United States. i TABLE OF CONTENTS PROSPECTUS SUMMARY This summary highlights selected information contained elsewhere in this prospectus and is qualified in its entirety by the more detailed information and financial statements included elsewhere in this prospectus. This summary does not contain all of the information you should consider before investing in our common stock. You should carefully read this entire prosp

View Full Filing

View this S-1/A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.